Sphingolipids in the Pathogenesis of Parkinson’s Disease and Parkinsonism
暂无分享,去创建一个
Hugo J. Bellen | H. Bellen | Paul C. Marcogliese | G. Lin | Guang Lin | Liping Wang | Liping Wang | Guang Lin
[1] Armin Giese,et al. Inhibition of mitochondrial fusion by α‐synuclein is rescued by PINK1, Parkin and DJ‐1 , 2010, The EMBO journal.
[2] Sohee Jeon,et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease , 2017, Science.
[3] A. Whitworth,et al. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin , 2015, Human molecular genetics.
[4] L. Polito,et al. Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease , 2016, Parkinson's disease.
[5] L. Bubacco,et al. LRRK2 deficiency impacts ceramide metabolism in brain. , 2016, Biochemical and biophysical research communications.
[6] C. Ross,et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.
[7] J. Jankovic,et al. Parkinsonism, movement disorders and genetics in frontotemporal dementia , 2016, Nature Reviews Neurology.
[8] D. Berg,et al. Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study , 2013, PloS one.
[9] Wenzhang Wang,et al. Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes , 2015, Nature Medicine.
[10] D. Krainc,et al. α-Synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models , 2016, Proceedings of the National Academy of Sciences.
[11] J. Allman,et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. , 2004, Molecular genetics and metabolism.
[12] D. Krainc,et al. Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity , 2012, The Journal of Neuroscience.
[13] G. Sobue,et al. Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site , 2013, Acta neuropathologica communications.
[14] D. Perl,et al. Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease , 1995, Nature Genetics.
[15] J. Shulman,et al. Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease , 2016, Acta neuropathologica communications.
[16] B. Ogretmen,et al. Ceramide induced mitophagy and tumor suppression. , 2015, Biochimica et biophysica acta.
[17] John Hardy,et al. Parkinson's disease , 2009, The Lancet.
[18] Masaki Tanaka,et al. Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous α-synuclein fibrils , 2015, Neurobiology of Disease.
[19] Jennifer C. Lee,et al. α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases* , 2011, The Journal of Biological Chemistry.
[20] A. Schapira,et al. Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease , 2013, Cell metabolism.
[21] D. Krainc,et al. Parkin Modulates Endosomal Organization and Function of the Endo-Lysosomal Pathway , 2016, Journal of Neuroscience.
[22] L. Partridge,et al. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin , 2016, The Journal of Neuroscience.
[23] R. Boot,et al. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases , 2016, FEBS letters.
[24] H. Christian,et al. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons , 2016, Stem cell reports.
[25] S. Chandra,et al. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease , 2017, The Journal of Neuroscience.
[26] S. D. de Jager,et al. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death , 2015, Human molecular genetics.
[27] J. Hardy,et al. Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction , 2015, Brain : a journal of neurology.
[28] L. Wrabetz,et al. Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity , 2016, The Journal of Neuroscience.
[29] M. Nalls,et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.
[30] Christer S. Ejsing,et al. The GARP complex is required for cellular sphingolipid homeostasis , 2015, eLife.
[31] Simon C. Potter,et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease , 2017, Brain : a journal of neurology.
[32] Silva Hecimovic,et al. Loss of Cathepsin B and L Leads to Lysosomal Dysfunction, NPC-Like Cholesterol Sequestration and Accumulation of the Key Alzheimer's Proteins , 2016, PloS one.
[33] H. Mortiboys,et al. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 , 2010, Neurology.
[34] RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. , 2013, Neuron.
[35] Nele A. Haelterman,et al. A mitocentric view of Parkinson's disease. , 2014, Annual review of neuroscience.
[36] P. Lockhart,et al. The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[37] M. Maffia,et al. Lipid profiling of parkin‐mutant human skin fibroblasts , 2017, Journal of cellular physiology.
[38] M. Haque,et al. Silencing of Glucocerebrosidase Gene in Drosophila Enhances the Aggregation of Parkinson's Disease Associated α-Synuclein Mutant A53T and Affects Locomotor Activity , 2018, Front. Neurosci..
[39] R. Nussbaum,et al. Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein*♦ , 2011, The Journal of Biological Chemistry.
[40] M. Nalls,et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.
[41] A. Whitworth,et al. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models , 2016, Scientific Reports.
[42] A. Pandey,et al. GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers , 2018, Proceedings of the National Academy of Sciences.
[43] P. Calabresi,et al. Lysosomal Dysfunction and α‐Synuclein Aggregation in Parkinson's Disease: Diagnostic Links , 2016, Movement disorders : official journal of the Movement Disorder Society.
[44] A. Gregory,et al. Neurodegeneration with brain iron accumulation. , 2005, Folia neuropathologica.
[45] Xiao-Min Wang,et al. GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A , 2015, Autophagy.
[46] C. Gieger,et al. The role of SCARB2 as susceptibility factor in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[47] G. Petsko,et al. Pharmacological chaperones stabilize retromer to limit APP processing. , 2014, Nature chemical biology.
[48] Tianhong Pan,et al. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. , 2008, Brain : a journal of neurology.
[49] S. Berkovic,et al. Abnormal Processing of Autophagosomes in Transformed B Lymphocytes from SCARB2-Deficient Subjects , 2013, BioResearch open access.
[50] S. Lindquist,et al. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.
[51] Elie Needle,et al. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. , 2015, Human molecular genetics.
[52] N. Avadhani,et al. Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.
[53] S.-J. Lee,et al. Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of α-synuclein aggregates , 2015, Cell Death and Disease.
[54] Jan Gründemann,et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.
[55] D. Vassilatis,et al. Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[56] Jennifer C. Lee,et al. Cysteine cathepsins are essential in lysosomal degradation of α-synuclein , 2015, Proceedings of the National Academy of Sciences.
[57] Peng Wang,et al. The genetics of Parkinson disease , 2018, Ageing Research Reviews.
[58] G. Rubboli,et al. SCARB2/LIMP2 deficiency in action myoclonus-renal failure syndrome. , 2016, Epileptic disorders : international epilepsy journal with videotape.
[59] P. Hogarth,et al. Neurodegeneration with Brain Iron Accumulation , 2004 .
[60] A. Takeda,et al. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease , 2014, Neurobiology of Disease.
[61] C. Nüsslein-Volhard,et al. Live Imaging of Neuronal Degradation by Microglia Reveals a Role for v0-ATPase a1 in Phagosomal Fusion In Vivo , 2008, Cell.
[62] J. Harper,et al. Building and decoding ubiquitin chains for mitophagy , 2018, Nature Reviews Molecular Cell Biology.
[63] J. Hardy,et al. Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.
[64] M. Brini,et al. The Close Encounter Between Alpha-Synuclein and Mitochondria , 2018, Front. Neurosci..
[65] Susan E. Brockerhoff,et al. Synaptojanin 1 Is Required for Endolysosomal Trafficking of Synaptic Proteins in Cone Photoreceptor Inner Segments , 2014, PloS one.
[66] R. Gershoni-baruch,et al. The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. , 2015, Parkinsonism & related disorders.
[67] K. Venderová,et al. Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson’s disease mutant of Leucine-rich repeat kinase 2 (LRRK2) , 2014, Molecular Neurodegeneration.
[68] T. Dawson,et al. Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes , 2017, Experimental Neurology.
[69] D. Sulzer,et al. Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.
[70] H. McBride,et al. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control , 2014, The EMBO journal.
[71] E. Masliah,et al. Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. , 2009, The American journal of pathology.
[72] H. Ko,et al. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model , 2018, Acta Neuropathologica Communications.
[73] K. Marder,et al. RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk , 2013, Neuron.
[74] J. Ferreira,et al. Serum lipid alterations in GBA-associated Parkinson's disease. , 2017, Parkinsonism & related disorders.
[75] A. F. Schinder,et al. αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson’s disease , 2017, Scientific Reports.
[76] P. Boya,et al. High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A , 2014, Cell Death and Differentiation.
[77] M. Farrer,et al. LRRK2 mutations in Parkinson disease , 2005, Neurology.
[78] Sarah C. Izen,et al. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice , 2015, Antioxidants & redox signaling.
[79] S. Sardi,et al. Modulation of &bgr;-glucocerebrosidase increases &agr;-synuclein secretion and exosome release in mouse models of Parkinson’s disease , 2018, Human molecular genetics.
[80] H. Bellen,et al. The retromer complex in development and disease , 2015, Development.
[81] Ying Sun,et al. Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies , 2011, Cell.
[82] H. Bellen,et al. Correction: The Retromer Complex Is Required for Rhodopsin Recycling and Its Loss Leads to Photoreceptor Degeneration , 2015, PLoS biology.
[83] M. Cookson,et al. LRRK2 at the interface of autophagosomes, endosomes and lysosomes , 2016, Molecular Neurodegeneration.
[84] S. Lindquist,et al. α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.
[85] E. Schuchman,et al. Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. , 1997, Genetic testing.
[86] J. Bronstein,et al. Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity , 2014, Disease Models & Mechanisms.
[87] H. Bellen,et al. Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to α-Synuclein Gain. , 2018, Cell metabolism.